FDA says that when a potential signal of a serious risk is identified from AEMS data, it will be posted in the required quarterly report in the quarter in which it is first identified. FDA also says that if additional safety information later develops around a previously posted signal, that follow-up will appear through new safety communications rather than being reposted as a new signal.
The agency is clear that a product appearing on the page does not mean FDA has concluded that the medicine caused the event or that patients should stop treatment. That distinction is essential for PV teams, because signal communication is about highlighting a concern under evaluation, not announcing a final causal verdict.
For safety-intelligence teams, the page is useful because it gives more visibility into how regulator-facing signal tracking works in practice. Teams that monitor it well may be better positioned to compare internal signal discussions with public FDA-facing developments. That is an inference from FDA’s published process.
0 Comments